Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

LongBio Pharma (Suzhou) Co., Ltd.
天辰生物醫藥(蘇州)股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 1779)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON OCTOBER 30, 2026

References are made to the notice (the "**EGM Notice**") of extraordinary general meeting (the "**EGM**") and the circular (the "**Circular**") of LongBio Pharma (Suzhou) Co., Ltd. (the "**Company**") both dated October 9, 2026. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the EGM Notice and the Circular.

The EGM was held at 4:00 p.m. on Friday, October 30, 2026 at Room 302, Building 88, No. 887 Zuchongzhi Road, Zhangjiang High-Tech Park, Pudong New District, Shanghai, PRC. All of the Directors attended the EGM in person or by electronic means.

As at the date of the EGM, the total number of issued Shares of the Company was 76,322,100, comprising 75,059,218 H Shares and 1,262,882 Unlisted Shares, which was the total number of Shares entitling the holders to attend and vote on the resolutions proposed at the EGM. The Company did not hold any treasury Shares (including any treasury Shares held or deposited with the CCASS established and operated by HKSCC) or repurchased Shares which are pending cancellation. No Shareholders were required under the Listing Rules to abstain from voting on the resolutions proposed at the EGM. There were no Shares entitling the Shareholders to attend and abstain from voting in favor of the resolutions proposed at the EGM as set out in Rule 13.40 of the Listing Rules. None of the Shareholders has stated his/her/its intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the EGM. The convening of the EGM was in compliance with the relevant requirements of the Company Law and the Articles of Association.

Shareholders and duly authorized proxies, holding a total of 15,166,638 Shares, representing approximately 19.87% of the total number of issued Shares, were present at the EGM. The resolutions at the EGM were put to vote by way of poll.

POLL RESULTS OF THE EGM

The Board is pleased to announce that the following resolutions have been duly passed at the EGM and the details of the poll results are set out as follows:

SPECIAL RESOLUTIONS		NUMBER OF VOTES (%)		
		FOR	AGAINST	ABSTAIN
1.	To consider and approve the Proposed Amendments to Articles 3, 6 and 20 of the Articles of Association for the purpose of reflecting the changes in the registered share capital and the structure of the share capital of the Company following the full exercise of the Over-allotment Option.	15,165,738 99.99%	0 0.00%	900 0.01%
2.	To consider and approve the Proposed Amendments to Article 69 of the Articles of Association for the purpose of aligning the provisions of the Articles of Association more closely with the applicable domestic laws and regulations.	15,165,738 99.99%	0 0.00%	900 0.01%
As more than two-thirds of the votes from Shareholders (including proxies thereof) attending and having the rights to vote at the EGM were cast in favor of the resolutions numbered 1 to 2, the resolutions were duly passed as special resolutions of the Company.				

The Company's H Share Registrar in Hong Kong, Tricor Investor Services Limited, and two Shareholder representatives of the Company were appointed as the scrutineers for the purpose of vote-taking at the EGM.

By order of the Board
LongBio Pharma (Suzhou) Co., Ltd.
Dr. Liu Heng
Chairman of the Board and Executive Director

Hong Kong, October 30, 2026

As at the date of this announcement, the Board comprises (i) Dr. LIU Heng, Dr. SUN Bill Nai-chau and Mr. XIE Ming as executive Directors; (ii) Mr. LIN Jian, Ms. GU Qin, Dr. XUE Di and Mr. XUE Kailu as non-executive Directors; and (iii) Mr. SIU Paul Yu Hay, Mr. RUAN Tim, Mr. YANG Chun and Mr. ZHOU Guofang as independent non-executive Directors.